Ep 42: RELATIVITY 020

SummaryJames' favorite moments from #ESMO24 include footie and a not-so-chance encounter with NEJM Editor-in-Chief, Eric Rubin. In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the Relativity 020 study, which focuses on Nivo Rela after PD-1 exposure in melanoma patients. They reflect on their experiences at ESMO, including networking and memorable moments, before diving into the details of the study, including patient cohorts, treatment efficacy, and the challenges faced in clinical trials. The conversation also touches on the role of CTLA-4 therapies and the complexities of treatment sequencing in melanoma care.Keywordsmelanoma, ESMO, Relativity 020, Nivo Rela, PD-1, CTLA-4, clinical trials, patient access, immunotherapy, oncologyTakeawaysThe Relativity 020 study explores Nivo Rela after PD-1 exposure in melanoma.Networking at ESMO is crucial for sharing insights and experiences.Patient access to treatments is a significant challenge in clinical trials.The efficacy of Nivo Rela in heavily pretreated patients is limited.CTLA-4 therapies show low response rates in PD-1 refractory patients.Understanding treatment sequences is essential for optimizing patient outcomes.The importance of academic trials in addressing knowledge gaps in melanoma treatment.Elevated LDH levels are a concerning biomarker in treatment response.Collaboration among investigators is vital for advancing melanoma research.The conversation highlights the need for ongoing research and trials in melanoma. Chapters00:00 Introduction and ESMO Highlights03:30 Reflections on ESMO 202406:21 The Relativity 020 Study Overview09:17 Patient Perspectives and Clinical Trials12:20 Challenges in European Clinical Trials15:36 Efficacy of NIVO-RELA in Refractory Melanoma18:40 Discussion on CTLA-4 Therapies21:21 Future Directions in Melanoma Treatment